FPE024 / FAPON - LARVOL DELTA

Fapon Biopharma and MOTE Therapeutics to Present Dual-Platform B-Cell Immunotherapy Franchise at BIO 2026 (PRNewswire) - "This franchise features two differentiated programs targeting CD19 and BCMA, designed to deliver potent and sustained B-cell depletion: FPE024, a potential best-in-class CD19×BCMA×CD3 tri-specific T-cell engager for autoimmune indications, with IND filing targeted Q1 2027; and MTX001, a CD19×BCMA in vivo CAR-T program powered by the mobilize tLNP platform, with an investigator-initiated first-in-human study expected in Q4 2026....Leading the clinical-stage pipeline is FP008, a global first-in-class PD1×IL10M fusion protein for immuno-oncology, currently in Phase I development with key readout anticipated in 2026....Both FP012 and FPE021 are entering IND-enabling CMC/GLP toxicology in 2026."

First-in-human • IND • New trial • P1 data • Preclinical • Gastrointestinal Cancer • Immunology • Inflammatory Bowel Disease • Solid Tumor • Systemic Lupus Erythematosus

A CD19/BCMA Dual-targeting VHH format T-cell Engager with Novel CD3 Binder for Enhanced Potency and Safety Profile (IMMUNOLOGY 2026) - "FPE024 is a potent CD19/BCMA dual-targeting T-cell engager that enables broad depletion of pathogenic B cells and plasma cells. Its strong preclinical efficacy and translational relevance support further development for autoimmune diseases requiring comprehensive B-cell depletion."

Clinical • IO biomarker • Late-breaking abstract • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CD19

Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025 (PRNewswire) - "Fapon Biopharma...is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center. The company will exhibit at Booth #1851, presenting its differentiated pipeline, including the flagship Phase 1 immunocytokine FP008, a portfolio of promising early-stage candidates for oncology and autoimmune diseases, and its suite of proprietary technology platforms, while actively seeking global partnerships...The company will also feature promising preclinical candidates targeting oncology (FP010, FP011, FPE021) and autoimmune diseases (FPE022, FPE024), highlighting its expanding research capabilities."

P1 data • Preclinical • Immunology • Solid Tumor